Trade Summary

4 days ago, Filius Bart, serving as Dir at ProQR Therapeutics N.V. (PRQR), purchased 150,000 shares at $1.72 per share, for a total transaction value of $257,925.00. Following this transaction, Filius Bart now holds 300,000 shares of PRQR.

This purchase represents a 100.00% increase in Filius Bart's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, July 17, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, July 21, 2026 at 8:00 AM ET, 4 days after the trade was made.

ProQR Therapeutics N.V. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.